ArticleAmerican journal of translational research2026
Tripterygium glycosides and mesenchymal stem cells combination alleviated Sjögren's syndrome Features in mice and modulated the GRO-α/CXCR2 axis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy and potential mechanisms of tripterygium glycosides (TG) and human umbilical cord mesenchymal stem cells (hUC-MSCs) in the treatment of primary Sjögren's syndrome (PSS).
methodsExperimental Sjögren's syndrome (ESS) mice were administered TG (20 or 40 mg/kg/d, via oral gavage) and/or hUC-MSCs (1 × 10^6 cells/mouse, via tail vein injection) for a duration of 21 consecutive days. The parameters analyzed included saliva volume, lymphocytic infiltration in submandibular glands (SGs), serum cytokines, immunoglobulins, and the expression of the growth-related oncogene-alpha (GRO-α)/CXC chemokine receptor 2 (CXCR2) axis, as well as aquaporins (AQP1, AQP5).
resultsCo-treatment with TG and hUC-MSCs resulted in a significant increase in saliva volume and a reduction in lymphocytic infiltration within the SGs. Additionally, this treatment decreased levels of pro-inflammatory cytokines (interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α) while enhancing the levels of anti-inflammatory cytokines (IL-10, IL-13) in serum, and modulated T helper (Th) 1 and Th2 cell populations. Furthermore, the combination therapy effectively suppressed elevated levels of immunoglobulins (immunoglobulin (Ig) M, IgG, IgA) in ESS mice. Mechanistically, the co-treatment inhibited the GRO-α/CXCR2 axis and upregulated the expression of AQP1 and AQP5 in SGs.
conclusionThe findings of this study suggest that co-treatment with TG and hUC-MSCs mitigates the symptoms of PSS by modulating inflammatory and immune responses and by inhibiting the GRO-α/CXCR2 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.